September 29, 2020 11:17 AM EDTUpdated 02:08 PM
R&D

My­ovant shows dis­ap­point­ing prostate can­cer da­ta on the way to the FDA, stock sinks

Max Gelman

Senior Editor

My­ovant $MY­OV has been prep­ping re­l­u­golix for ad­vanced prostate can­cer over the last sev­er­al months, look­ing to im­prove up­on the old stan­dard in Ab­b­Vie …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times